RxDoctor Payments Data

Oladapo Fawibe, MD

Internal Medicine · Augusta, GANPI 1225031651

Payments from drug & device makers

$79,475in general payments, 2019–2025

Across 260 payments — averaging $305.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$52K
  • Shire North American Group Inc$23K
  • Novo Nordisk$2K
  • AstraZeneca$869
  • Bayer$494
  • GSK$385
  • plus $1K from 16 others

What the payments were for

  • Consulting fees$74,85594%
  • Food & beverage$4,5996%
  • Education$210%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$79,475 in reported general payments places this provider in the 95th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$156,508
Medicare patients
167
Services billed
2,293

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin101$103,481
OzempicSemaglutide50$84,971
RybelsusSemaglutide40$63,676
JanuviaSitagliptin Phosphate49$52,356
EliquisApixaban45$44,010
MounjaroTirzepatide20$29,780
FarxigaDapagliflozin Propanediol27$27,162
LinzessLinaclotide33$23,393
Tresiba Flextouch U-100Insulin Degludec38$18,853
JanumetSitagliptin Phos/Metformin Hcl15$16,684
KerendiaFinerenone22$16,082
EntrestoSacubitril/Valsartan23$15,018
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$12,782
Breo ElliptaFluticasone/Vilanterol24$11,501
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$8,716

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,548$148,64790 claims
Boehringer IngelheimJardiance$122$103,481101 claims
MerckJanuvia, Janumet$22$69,04164 claims
PfizerEliquis, Premarin$87$49,49662 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$869$46,29071 claims
Lilly USA, LLCMounjaro$128$29,78020 claims
AbbVieLinzess$313$23,39333 claims
GSKBreo Ellipta, Trelegy Ellipta$385$20,21738 claims
BayerKerendia$494$16,08222 claims
NovartisEntresto$55$15,01823 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Augusta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →